Skip to main content

Pyxis Oncology, Inc 10-Q for FY2026 Q3

Pyxis Oncology, Inc. (PYXS)

10-Q 2026-11-05 For: 2026-09-30
View Original
Added on November 05, 2026

About this 10-Q

Pyxis Oncology, Inc filed this 10-Q on November 5, 2026, covering the quarter ended September 30, 2026 (FY2026 Q3).

Pyxis Oncology reported MICVO’s 36% confirmed ORR and 94% DCR in 2L+ R/M HNSCC, plans the global pivotal Phase 3 HeadlinerSM trial for mid-2027, and expects resources to fund operations into the first half of 2028. AI summary

Headline figures

Quarter ended September 30, 2026, as reported in this filing, compared with the same period a year earlier where the filing states it.

Net loss
$19.98M
compared with a net loss of $22M a year earlier
Diluted EPS
-$0.24
compared with -$0.35 a year earlier